Leerink Partners lowers Belite Bio's EPS forecast for FY 2028

Summary

Leerink Partners adjusted its earnings forecast for Belite Bio, Inc. (NASDAQ: BLTE), lowering its expected earnings per share for the fiscal year 2028 from $4.60 to $4.40. The current consensus for the company’s earnings per share is -$1.17. In its recent quarterly report, Belite Bio reported an earnings per share of -$0.32, failing to meet expectations. Analysts from HC Wainwright, Cantor Fitzgerald, and Benchmark maintain positive ratings on the stock, with target prices between $80.00 and $100.00. The stock opened at $58.88 with a market capitalization of $1.87 billion, and a price-to-earnings ratio of -53.04. Market Beat

Impact Analysis

This is a company-level event, as it’s specific to Belite Bio’s earnings forecast and financial performance. The downward revision by Leerink Partners indicates potential concerns about the company’s ability to achieve previous financial targets. However, other analysts remain optimistic, suggesting confidence in Belite Bio’s long-term potential. The stock’s negative price-to-earnings ratio reflects current financial challenges, but high target prices from other analysts imply expected future growth. Investors should consider the mixed sentiment and assess if the current valuation aligns with their risk tolerance and investment strategy. Opportunities may exist for those seeing potential in biotechnology advancements that Belite Bio represents, while risks include the company’s underperformance in recent earnings reports. Market Beat